Hepatitis B and A vaccination in HIV-infected adults: A review

References

• Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. Lancet 2014;384:241-8.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention CDC. CDC Features: World Hepatitis Day 2014 - July 28th CDC Features. Atlanta: CDC; 2014 [updated July 2014]; Available at: http://www.cdc.gov/Features/WorldHepatitisDay/
   Google Scholar
• Centers for Disease Control and Prevention (CDC). HIV and Viral Hepatitis Fact Sheet. Atlanta: CDC; 2013 [updated March 2014]; Available at: http://www.cdc.gov/hiv/pdf/library_factsheets_HIV_and_viral_Hepatitis.pdf
   Google Scholar
• World Health Organization. Hepatitis A. Fact Sheet Nº328. Geneva: WHO; 2008 [updated June 2014]; Available at: http://www.who.int/mediacentre/factsheets/fs328/en/
   Google Scholar
• Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002;34:379-85.
   PubMed Web of Science ®Google Scholar
• Laurence JC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 2005; 118(Supp10A):75S-83S.
   PubMed Web of Science ®Google Scholar
• Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect. Dis 2012;12:966-76.
   PubMed Web of Science ®Google Scholar
• Phung BC, Launay O. Vaccination against viral hepatitis of HIV-1 infected patients. Hum Vaccin Immunother 2012;8:554-9.
   PubMed Web of Science ®Google Scholar
• Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-9.
   PubMed Web of Science ®Google Scholar
• Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al.; Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20.
   PubMedGoogle Scholar
• WHO Regional Office for Europe. Management of hepatitis B and HIV coinfection. Clinical Protocol for the WHO European Region (2011 revision). Copenhagen: WHO, 2011 [accessed September 2014]. Available at: http://www.euro.who.int/__data/assets/pdf_file/0011/152012/e95792.pdf
   Google Scholar
• Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
   PubMed Web of Science ®Google Scholar
• Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010;17:879-86.
   PubMed Web of Science ®Google Scholar
• Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009;49(5 Suppl):S138-45.
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 Suppl):S6-9.
   PubMed Web of Science ®Google Scholar
• Oliveira SB, Merchán-Hamann E, Amorim LD. HIV/AIDS coinfection with the hepatitis B and C viruses in Brazil. Cad Saude Publica 2014;30:433-8.
   PubMed Web of Science ®Google Scholar
• Matthews PC, Geretti AM, Goulder PJR, Klenerman P. Epidemiology and impact of HIV coinfection with Hepatitis B and Hepatitis C viruses in Sub-Saharan Africa. J Clin Virol 2014;61:20-33.
   PubMed Web of Science ®Google Scholar
• Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection inSouthern Taiwan, 2000-2005: Upsurge in Hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008;107:404-11.
   PubMed Web of Science ®Google Scholar
• Vento S, di Perri G, Luzzati R, Cruciani M, Garofano T, Mengoli C, et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989;1:332-3.
   PubMed Web of Science ®Google Scholar
• Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994;18:339-47.
   PubMed Web of Science ®Google Scholar
• Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 1991;163:1138-40.
   PubMed Web of Science ®Google Scholar
• Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82.
   PubMed Web of Science ®Google Scholar
• Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Infuence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
   PubMed Web of Science ®Google Scholar
• Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol 2014;20:14598-614.
   PubMed Web of Science ®Google Scholar
• Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012;205:185-93.
   PubMed Web of Science ®Google Scholar
• Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS 1992;6:571-4.
   PubMed Web of Science ®Google Scholar
• Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-41.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009;84:405-20.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention (CDC). Hepatitis B. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015 [accessed May 2014]. Available at: www.cdc.gov/vaccines/pubs/pinkbook/hepb.html
   Google Scholar
• U.S. Department of Health and Human Servides. U.S. Food and Drug Administration (FDA). Vaccines, blood & biologics [accessed January 2015]. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/default.htm
   Google Scholar
• European Medicines Agency (EMA). European public assessment reports (EPAR) for human medicines. [accessed January 2015]. Available at: http://www.ema.europa.eu/ema/
   Google Scholar
• Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? J Infect Dis 1999;179:489-92.
   PubMed Web of Science ®Google Scholar
• Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, et al. Hepatitis B vaccination in infancy in The Gambia: Protection against carriage at 9 years of age. Vaccine 1999;17:2946-50.
   PubMed Web of Science ®Google Scholar
• Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008;27:881-5.
   PubMed Web of Science ®Google Scholar
• Keating GM, Noble S, Averhoff FM, Belloni C, Duval B, Goldwater PN, et al. Recombinant hepatitis B vaccine (Engerix-B®): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003;63:1021-51.
   PubMed Web of Science ®Google Scholar
• Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010;28:626-31.
   Web of Science ®Google Scholar
• Gunn TR, Bosley A, Woodfield DG. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. N Z Med J 1989;102:1-3.
   PubMedGoogle Scholar
• Ahmed S, Perveen I. Safety, Immunogenicity and reactogenicity of recombinant hepatitis B vaccine Engerix-B. Immunology 2011;135:81.
   PubMed Web of Science ®Google Scholar
• Niu MT, Rhodes P, Salive M, Lively T, Davis DM, Black S, et al. Comparative safety of two recombinant hepatitis B vaccines in children: Data from the vaccine adverse event reporting system (VAERS) and vaccine safety datalink (VSD). J Clin Epidemiol 1998;51:503-10.
   PubMed Web of Science ®Google Scholar
• Zahradnik JM, Couch RB, Gerin JL. Safety and immunogenicity of a purified hepatitis B virus vaccine prepared by using recombinant DNA technology. J Infect Dis 1987;155:903-8.
   PubMed Web of Science ®Google Scholar
• Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995;16:12-7.
   PubMed Web of Science ®Google Scholar
• Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, et al. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol 2013;48:1373-83.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras a , Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1460-6.
   PubMed Web of Science ®Google Scholar
• Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS 2013;24:117-22.
   PubMed Web of Science ®Google Scholar
• Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
   PubMed Web of Science ®Google Scholar
• Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005;23:2902-8.
   PubMed Web of Science ®Google Scholar
• Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S. Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007;38:680-5.
   PubMedGoogle Scholar
• Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008;19:600-4.
   PubMed Web of Science ®Google Scholar
• Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008; 12:e77-83.
   PubMed Web of Science ®Google Scholar
• Psevdos G, Kim JH, Groce V, Sharp V. Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010;24:403-7.
   PubMed Web of Science ®Google Scholar
• Pettit NN, DePestel DD, Malani PN, Riddell J 4th. Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin Trials 2010;11:332-9.
   PubMed Web of Science ®Google Scholar
• Launay O, van der Vliet D, Rosenberg AR, Michel M-L, Piroth L, Rey D, Colin de Verdière N, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011;305:1432-40.
   PubMed Web of Science ®Google Scholar
• Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: A randomized, controlled trial. PLoS One 2013;8:e80409.
   PubMed Web of Science ®Google Scholar
• Rock C, de Barra E de, Sadlier C, Kelly S, Dowling C, McNally C, et al. Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. J Infect Public Health 2013;6:173-8.
   PubMedGoogle Scholar
• Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005;41:1045-8.
   PubMed Web of Science ®Google Scholar
• De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4.
   PubMed Web of Science ®Google Scholar
• Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006;3:9.
   PubMedGoogle Scholar
• Sasaki Md, Foccacia R, de Messias-Reason IJ. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003;21:4545-9.
   PubMed Web of Science ®Google Scholar
• Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006;24:7124-8.
   PubMed Web of Science ®Google Scholar
• Potsch DV, Oliveira ML, Ginuíno C, Miguel JC, Oliveira SA, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010;28:1447-50.
   PubMed Web of Science ®Google Scholar
• Potsch DV, Camacho LA, Tuboi S, Villar LM, Miguel JC, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012;30:5973-7.
   PubMed Web of Science ®Google Scholar
• Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9.
   PubMed Web of Science ®Google Scholar
• Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010;28:5597-604.
   PubMed Web of Science ®Google Scholar
• Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis 2013;207:402-10.
   PubMed Web of Science ®Google Scholar
• Kim JH, Psevdos G, Groce V, Sharp V. Persistence of protective hepatitis B surface antibody titers after successful double-dose hepatitis B virus rescue vaccination in HIV-infected patients. Gut Liver 2012; 6:86-91.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009;27:17-22.
   PubMed Web of Science ®Google Scholar
• De Vries-Sluijs TE, Hansen BE, van Doornum GJ, Springeling T, Evertsz NM, de Man RA, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197:292-4.
   PubMed Web of Science ®Google Scholar
• Zhao D-M, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006;107:3925-32.
   PubMed Web of Science ®Google Scholar
• Goncalves L, Albarran B, Salmen S, Borges L, Fields H, Montes H, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004;326:20-8.
   PubMed Web of Science ®Google Scholar
• Okoye AA, Picker LJ. CD4+ T-Cell Depletion In HIV Infection: Mechanisms Of Immunological Failure. Immunol Rev 2013; 254:54-64.
   PubMed Web of Science ®Google Scholar
• Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol 2000;1:285-9.
   PubMed Web of Science ®Google Scholar
• Powis JE, Raboud J, Ostrowski M, Loutfy MR, Kovacs C, Walmsley SL. The Recombinant Hepatitis B Surface Antigen Vaccine in Persons With HIV: Is Seroconversion Sufficient for Long-term Protection? J Infect Dis 2012;205:1534-8.
   PubMed Web of Science ®Google Scholar
• Lopes VB, Hassing RJ, De Vries-Sluijs TEMS, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine 2013;31:1040-4.
   PubMed Web of Science ®Google Scholar
• Titanji K, De Milito A, Cagigi A, Thorstensson R, Grützmeier S, Atlas A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006;108:1580-7.
   PubMed Web of Science ®Google Scholar
• Valour F, Cotte L, Voirin N, Godinot M, Ader F, Ferry T, et al. Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients. Vaccine 2014;32:4558-64.
   PubMed Web of Science ®Google Scholar
• Price H, Bansi L, Sabin CA, Bhagani S, Burroughs A, Chadwick D, et al. Hepatitis B Virus Infection in HIV-Positive Individuals in the UK Collaborative HIV Cohort (UK CHIC) Study. 2012;7:e49314.
   Google Scholar
• Martins S, do Livramento A, Andrigueti M, Kretzer IF, Machado MJ, Spada C et al. Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil. Braz J Infect Dis 2015;19:181-6.
   PubMed Web of Science ®Google Scholar
• Ho YL, Enohata T, Lopes MH, De Sousa Dos Santos S. Vaccination in Brazilian HIV-infected adults: a cross-sectional study. AIDS Patient Care STDS 2008;22:65-70.
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009 Apr 10;58(RR-4):1-207.
   Google Scholar
• Geretti AM, BHIVA Immunization Writing Committee, Brook G, Cameron C, Chadwick D, Heyderman RS, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008;9:795-848.
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. Clinical management and treatment of HIV-infected patients in Europe. V 7.1. November 2014. Zurich: EACS, 2014 [accessed December 2014]. Available at: http://www.eacsociety.org/files/guidelines-7.1-english.pdf.
   Google Scholar
• World Health Organization. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Geneva: WHO; 2010 [updated January 2015]; Available at: http://apps.who.int/iris/bitstream/10665/70180/1/WHO_IVB_10.01_eng.pdf
   Google Scholar
• Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2012;4:68-73.
   PubMedGoogle Scholar
• Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol Rev 2006;28:101-11.
   PubMed Web of Science ®Google Scholar
• Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010;28:6653-7.
   PubMed Web of Science ®Google Scholar
• Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003; 21:2224-33.
   PubMed Web of Science ®Google Scholar
• Broman M, Jokinen S, Kuusi M, Lappalainen M, Roivainen M, Liitsola K, et al. Epidemiology of hepatitis A in Finland in 1990-2007. J Med Virol 2010;82:934-41.
   PubMed Web of Science ®Google Scholar
• WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec 2012;87:261-76.
   PubMedGoogle Scholar
• Fainboim H, González J, Fassio E, Martínez A, Otegui L, Eposto M, et al. Prevalence of hepatitis viruses in an anti-human immunodeficiency virus-positive population from Argentina. A multicentre study. J Viral Hepat 1999;6:53-7.
   PubMed Web of Science ®Google Scholar
• Costa-Mattioli M, Allavena C, Poirier A-S, Billaudel S, Raffi F, Ferré V. Prolonged hepatitis A infection in an HIV-1 seropositive patient. J Med Virol 2002;68:7-11.
   PubMed Web of Science ®Google Scholar
• Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286-90.
   PubMed Web of Science ®Google Scholar
• Sloan DS. The utilisation of hepatitis A vaccine 1992-1994. Health Bull (Edinb) 1996;54:140-51.
   PubMedGoogle Scholar
• Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004;22:4342-50.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 2004;3:249-67.
   PubMedGoogle Scholar
• Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328-34.
   PubMed Web of Science ®Google Scholar
• Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 1994;44:443-5.
   PubMed Web of Science ®Google Scholar
• Zhang ZL, Zhu XJ, Shan AL, Gao ZG, Zhang Y, Ding YX, et al. Effectiveness of 10-year vaccination (2001-2010) on Hepatitis A in Tianjin, China. Hum Vaccin Immunother 2014;10:1008-12.
   Web of Science ®Google Scholar
• Bialek SR, Thoroughman DA, Hu D, Simard EP, Chattin J, Cheek J, et al. Hepatitis A incidence and hepatitis a vaccination among American Indians and Alaska Natives, 1990-2001. Am J Public Health 2004;94:996-1001.
   PubMed Web of Science ®Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-10.
   PubMed Web of Science ®Google Scholar
• Bian GL, Ma R, Dong HJ, Ni HX, Hu FJ, Chen YR, et al. Long-term clinical observation of the immunogenicity of inactivated hepatitis A vaccine in children. Vaccine 2010;28:4798-801.
   PubMed Web of Science ®Google Scholar
• Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013;207:493-6.
   PubMed Web of Science ®Google Scholar
• Raczniak GA, Thomas TK, Bulkow LR, Negus SE, Zanis CL, Bruce MG, et al. Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children. Vaccine 2013;31:2152-5.
   PubMed Web of Science ®Google Scholar
• Bovier PA, Bock J, Ebengo TF, Frösner G, Glaus J, Herzog C, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010;82:1629-34.
   PubMed Web of Science ®Google Scholar
• Demicheli V, Tiberti D. The effectiveness and safety of hepatitis A vaccine: a systematic review. Vaccine 2003;21:2242-5.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Hansen J, Lewis E, Su L, Coplan P. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (VAQTA, Merck) in children and adults. Vaccine 2004;22:766-72.
   PubMed Web of Science ®Google Scholar
• Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55:1-23.
   PubMedGoogle Scholar
• Li RC, Li Y, Yi N, Huang L, Wan Z, Zhang Y, et al. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China. Pediatr Infect Dis J 2013;32:e77-81.
   PubMed Web of Science ®Google Scholar
• Wallace MR, Brandt CJ, Earhart KC, Kuter BJ, Grosso AD, Lakkis H, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207-13.
   PubMed Web of Science ®Google Scholar
• Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat 2006;13:81-6.
   PubMed Web of Science ®Google Scholar
• Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005;19:1702-4.
   PubMed Web of Science ®Google Scholar
• Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007;14:189-93.
   PubMed Web of Science ®Google Scholar
• Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr 2008;49:272-5.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, Weintrob A, et al. Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 2011;203:1815-23.
   PubMed Web of Science ®Google Scholar
• Kourkounti S, Mavrianou N, Paparizos VA, Kyriakis K, Hatzivassiliou M, Kordosis T, et al. Immune response to hepatitis A vaccination in HIV-infected men in Greece. Int J STD AIDS 2012;23:464-7.
   PubMed Web of Science ®Google Scholar
• Tseng YT, Chang SY, Liu WC, Sun HY, Wu CH, Wu PY, et al. Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men. Hepatology 2013;57:1734-41.
   PubMed Web of Science ®Google Scholar
• Jimenez HR, Hallit RR, Debari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable? Vaccine 2013;31:1328-33.
   PubMed Web of Science ®Google Scholar
• Kourkounti S, Papaizos V, Leuow K, Kordosis T, Antoniou C. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol 2013;26:357-63.
   PubMed Web of Science ®Google Scholar
• Jablonowska E, Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int J STD AIDS 2014;25:745-50.
   PubMed Web of Science ®Google Scholar
• Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine 2012; 30:3703-9.
   PubMed Web of Science ®Google Scholar
• Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327-31.
   PubMed Web of Science ®Google Scholar
• Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4 +lymphocytes. AIDS 1994;8:469-76.
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005;191:1435-41.
   PubMed Web of Science ®Google Scholar
• Armstrong KE, Bush HM, Collins JD, Feola DJ, Caldwell GC, Thornton AC. Role of CD4 count in immunity development after hepatitis A and B vaccination among HIV-infected patients: Kentucky, 2002-2007. J Int Assoc Physicians AIDS Care (Chic) 2010;9:179-86.
   PubMedGoogle Scholar
• Winter AP, Follett EA, McIntyre J, Stewart J, Symington IS. Influence of smoking on immunological responses to hepatitis B vaccine. Vaccine 1994;12:771-2.
   PubMed Web of Science ®Google Scholar
• Kernéis S, Desaint C, Brichler S, Rey D, Belarbi L, Gordien E et al. Long-term persistence of humoral immunity after hepatitis A vaccination in HIV-infected adults. J Acquir Immune Defic Syndr 2011;57:e63-6.
   PubMed Web of Science ®Google Scholar
• Saksawad R, Likitnukul S, Warachit B, Hanvivatvong O, Poovorawan Y, Puripokai P. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children. Vaccine 2011;29:4735-8.
   PubMed Web of Science ®Google Scholar
• Bodsworth NJ, Neilsen GA, Donovan B. The effect of immunization with inactivated hepatitis A vaccine on the clinical course of HIV-1 infection: 1-year follow-up. AIDS 1997;11:747-9.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Hepatitis A. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S (Eds). Public Health Foundation, Washington, DC 2015 [accessed May 2014]. Available at: www.cdc.gov/vaccines/pubs/pinkbook/hepa.html
   Google Scholar
• Gov.UK. Chapter 18: Hepatitis B . In: Green Book: Immunisation against infectious disease, Salisbury D and Ramsay M (Eds). Public Health England, London, March 2013 [updated December 2013] [accessed September 2014]; Available at: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18
   Google Scholar
• Overton E, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly W, et al. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. Open Virol J 2011;5:109-13.
   PubMedGoogle Scholar